Recombinant Human Amyloid beta A4 Protein
Catalog #: DRA20 Derived From: Human Cells
Recombinant Human Amyloid β A4 Protein/APP is produced by our Mammalian expression system and the target gene encoding Leu18-Leu305 is expressed with a 6His tag at the C-terminus.
Names(Known as):Amyloid Beta A4 Protein; ABPP; APPI; APP; Alzheimer Disease Amyloid Protein; CerebralVascularAmyloid Peptide; CVAP; PreA4; Protease Nexin-II; PN-II; APP
Mol Mass: 33.6kDa AP Mol Mass: 50kDa, reducing conditions
Purity: Greater than 95% as determined by reducing SDS-PAGE.
Supplied as a 0.2 μm filtered solution of 20mM PB,150mM NaCl,pH7.4.
The product is shipped on dry ice pack.
Upon receipt, store it immediately at the temperature listed below.
Reconstituted protein solution should be stored at ≤ -20°C.
Affinity purification chromatography.
Immunogen, calibrator or standard.
Amyloid β A4 Protein (APP) is an integral membrane protein that belongs to the APP family. APP contains one BPTI/Kunitz inhibitor domain. APP is expressed in all fetal tissues, with the highest expression levels observed in the brain, kidney, heart, and spleen. APP is a cell surface receptor and performs physiological functions on the surface of neurons relevant to neurite growth, neuronal adhesion, and axonogenesis. APP plays a role in cell mobility and transcription regulation through protein-protein interactions. APP also promotes transcription activation through binding to APBB1-KAT5 and inhibits Notch signaling through interaction with Numb. Mutations in APP are associated with Alzheimer's disease.
FOR RESEARCH OR FURTHER MANUFACTURING USE ONLY